| Literature DB >> 35075100 |
Fan Ping1, Yanxia Wang1, Xia Shen1, Conge Tan2, Lin Zhu1, Wenwen Xing2, Jun Xu3.
Abstract
BACKGROUND Heat-clearing and detoxifying herbs (HDHs) play an important role in the prevention and treatment of coronavirus infection. However, their mechanism of action needs further study. This study aimed to explore the anti-coronavirus basis and mechanism of HDHs. MATERIAL AND METHODS Database mining was performed on 7 HDHs. Core ingredients and targets were screened according to ADME rules combined with Neighborhood, Co-occurrence, Co-expression, and other algorithms. GO enrichment and KEGG pathway analyses were performed using the R language. Finally, high-throughput molecular docking was used for verification. RESULTS HDHs mainly acts on NOS3, EGFR, IL-6, MAPK8, PTGS2, MAPK14, NFKB1, and CASP3 through quercetin, luteolin, wogonin, indirubin alkaloids, ß-sitosterol, and isolariciresinol. These targets are mainly involved in the regulation of biological processes such as inflammation, activation of MAPK activity, and positive regulation of NF-kappaB transcription factor activity. Pathway analysis further revealed that the pathways regulated by these targets mainly include: signaling pathways related to viral and bacterial infections such as tuberculosis, influenza A, Ras signaling pathways; inflammation-related pathways such as the TLR, TNF, MAPK, and HIF-1 signaling pathways; and immune-related pathways such as NOD receptor signaling pathways. These pathways play a synergistic role in inhibiting lung inflammation and regulating immunity and antiviral activity. CONCLUSIONS HDHs play a role in the treatment of coronavirus infection by regulating the body's immunity, fighting inflammation, and antiviral activities, suggesting a molecular basis and new strategies for the treatment of COVID-19 and a foundation for the screening of new antiviral drugs.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35075100 PMCID: PMC8800284 DOI: 10.12659/MSM.934102
Source DB: PubMed Journal: Med Sci Monit ISSN: 1234-1010
Figure 1The integrated workflow. (Microsoft Word 2010).
Figure 2Schematic diagram of the screening of core ingredients and core targets. (Microsoft Word 2010).
Figure 3Protein interaction networks of related genes in the treatment of coronavirus infection with HDHs. (Cytoscape 3.7.1).
Figure 4Active ingredient-target-disease network diagram. (Cytoscape 3.7.1). There are 115 nodes and 211 edges in the network, among which blue rectangles represent ingredients, green ellipses represent targets, and orange diamonds represent disease.
Active ingredient list of HDHs in the treatment of coronavirus infection.
| MOL ID | Ingredient | Classification | Chem 2D | Core target |
|---|---|---|---|---|
| MOL000098 | Quercetin | Flavonoid |
| IL6, EGFR, CASP3, RELA, PTGS2, PPARG, NOS3 |
| MOL000006 | Luteolin | Flavonoid |
| IL6, EGFR, CASP3, RELA, PTGS2, PPARG, |
| MOL000173 | Wogonin | Flavonoid |
| IL6, CASP3, MAPK14, RELA, PTGS2, PPARG, LCK |
| MOL000422 | Kaempferol | Flavonoid |
| CASP3, MAPK8, RELA, PTGS2, PPARG, NOS3 |
| MOL008228 | Andrographin | Flavonoid |
| PTGS2, NOS3 |
| MOL003095 | 5-hydroxy-7-methoxy-2-(3,4,5-trimethoxyphenyl)chromone | Flavonoid |
| MAPK14, PTGS2, PPARG, NOS3, LCK |
| MOL001689 | Acacetin | Flavonoid |
| CASP3, RELA, PTGS2, LCK |
| MOL008239 | Quercetin tetramethyl(3′,4′,5,7) ether | Flavonoid |
| MAPK14, PTGS2, PPARG, NOS3 |
| MOL008204 | Mono-O-methylwightin | Flavonoid |
| MAPK14, PTGS2, PPARG, NOS3 |
| MOL008209 | Deoxycamptothecine | Alkaloid |
| MAPK14, PTGS2, PPARG, NOS3 |
| MOL003283 | (2R,3R,4S)-4-(4-hydroxy-3-methoxy-phenyl)-7-methoxy-2,3-dimethylol-tetralin-6-ol (Isolariciresinol) | Lignans |
| MAPK14, PTGS2, PPARG, NOS3 |
| MOL002928 | Oroxylin a | Flavonoid |
| IL6, CASP3, PTGS2, LCK |
| MOL002309 | Indirubin | Alkaloid |
| MAPK14, PTGS2, PPARG, NOS3 |
| MOL008206 | Moslosooflavone | Flavonoid |
| MAPK14, PTGS2, PPARG, LCK |
| MOL008230 | Andrographidine F | Flavonoid |
| MAPK14, PTGS2, PPARG |
| MOL000358 | β-sitosterol | Steroid |
| CASP3, NFKB1, PTGS2 |
| MOL001551 | Betulin | Terpenoid |
| MAPK3, MAPK1, NFKB1 |
Figure 5GO and KEGG pathway enrichment analysis. (clusterProfiler software package on the R 4.0.3 and bioinformatics platform). (A) GO enrichment analysis diagram. (B) Functional annotation diagram.
Figure 6Heat map of molecular docking results. (TBTools).
Figure 7Schematic diagram of molecular docking. (SYBYL-X 2.0). (A) With the small molecule ligand of wogonin as the center, the amino acid residues of ACE2 within the range of 5A form an added structure to the surface of the interface pocket; (B) With the small molecule ligand of isolariciresinol as the center, the amino acid residues of ACE2 within the range of 5A form an added structure to the surface of the interface pocket; (C) With the small molecule ligand of quercetin as the center, the amino acid residues of NOS3 within the range of 5A form an added structure to the surface of the interface pocket.
The molecular docking results of the main active ingredients and the core targets.
| Compound | Total-Score | |||||||
|---|---|---|---|---|---|---|---|---|
| NOS3 | CASP3 | ACE2 | EGFR | IL6 | PTGS2 | MAPK14 | NFKB1 | |
| MOL000098 | 3.70 | 3.34 | 3.30 | 5.46 | 4.48 | 3.82 | 5.63 | 4.53 |
| MOL000006 | 6.64 | 4.08 | 3.05 | 4.68 | 4.21 | 3.28 | 5.22 | 5.87 |
| MOL000422 | 3.51 | 4.24 | 2.67 | 4.46 | 3.26 | 4.12 | 5.88 | 4.13 |
| MOL000173 | 4.24 | 2.82 | 3.43 | 5.59 | 3.42 | 2.54 | 7.23 | 5.11 |
| MOL008239 | 7.57 | 5.34 | 3.72 | 4.96 | 6.37 | 5.18 | 7.11 | 5.85 |
| MOL008204 | 6.15 | 3.36 | 1.66 | 5.03 | 3.76 | 4.64 | 7.42 | 5.17 |
| MOL008228 | 4.29 | 3.85 | 3.09 | 3.59 | 2.99 | 5.36 | 7.00 | 6.03 |
| MOL003095 | 8.02 | 4.77 | 2.27 | 5.20 | 4.94 | 4.13 | 5.65 | 7.02 |
| MOL008230 | 6.66 | 3.56 | 3.70 | 5.26 | 3.86 | 4.04 | 8.46 | 5.32 |
| MOL008209 | 6.57 | 3.62 | 3.60 | 4.71 | 3.99 | 2.58 | 1.10 | 4.17 |
| MOL003283 | 5.60 | 2.05 | 3.94 | 5.22 | 4.35 | 3.94 | 7.32 | 4.84 |
| MOL002928 | 4.24 | 3.44 | 2.63 | 5.90 | 3.38 | 2.04 | 6.25 | 6.60 |
| MOL001689 | 5.69 | 4.56 | 1.72 | 4.38 | 4.89 | 3.65 | 5.21 | 4.42 |
| MOL000358 | 7.08 | 3.24 | 3.58 | 5.60 | 5.29 | 6.86 | 5.23 | −1.45 |
| MOL002309 | 4.36 | 3.08 | 3.13 | 4.30 | 3.15 | 4.08 | 6.89 | 5.16 |
| MOL000449 | 8.76 | 3.12 | 6.37 | 5.44 | 5.21 | 6.01 | 4.01 | −1.39 |
| MOL001771 | 7.03 | 2.85 | 4.74 | 5.36 | 5.81 | 3.80 | 4.69 | −2.77 |
| MOL001781 | 3.77 | 2.00 | 2.24 | 2.75 | 2.83 | 2.64 | 6.08 | 4.41 |
| MOL001810 | 5.30 | 1.82 | 2.06 | 4.69 | 2.18 | 2.53 | 4.10 | 3.39 |
| MOL002322 | 4.13 | 0.56 | 3.71 | 4.69 | 2.77 | 3.12 | 2.58 | 2.48 |
| MOL008206 | 3.74 | 3.98 | 3.04 | 4.73 | 4.57 | 3.01 | 6.21 | 4.61 |
| MOL001551 | 4.01 | 1.72 | 3.62 | 3.95 | 4.39 | 2.41 | −13.95 | −6.90 |
| MOL002773 | 6.36 | −0.50 | 2.94 | 3.10 | 5.03 | 4.78 | 2.20 | 5.76 |
| MOL003044 | 5.46 | 3.04 | 2.98 | 5.46 | 3.49 | 4.04 | 5.27 | 5.29 |
| MOL002311 | 3.77 | 3.84 | 3.14 | 4.25 | 3.34 | 3.94 | 7.90 | 1.85 |
| MOL001767 | 5.73 | 3.30 | 2.12 | 3.40 | 3.46 | 3.62 | 4.46 | 5.01 |
| MOL001735 | 4.69 | 3.15 | 2.78 | 4.58 | 4.48 | 2.92 | 4.81 | 4.21 |
| RIBAVIRIN | 3.37 | 2.71 | 3.35 | 4.93 | 2.54 | 3.35 | 2.43 | 4.52 |
Figure 8Typical binding mode of the trusted target proteins with the active ingredients of HDHs by molecular docking. (Discovery Studio 2016 Client) (A) Quercetin tetramethyl(3′,4′,5,7) ether and IL6; (B) Quercetin tetramethyl(3′,4′,5,7) ether and CASP3; (C) Stigmasterol and ACE2; (D) 5-hydroxy-7-methoxy-2-(3,4,5-trimethoxyphenyl)chromone and NFKB1. (The rest of the figures have been uploaded to the attachment).